이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

폐색전증 타입 구분을 위한 반복 검사 (RE-TyPE)

2026년 10월 7일 업데이트: Rickard Zeijlon, Sahlgrenska University Hospital

반복 검사를 통한 폐색전증 분류 (RE-TyPE)

PURPOSE

The two related purposes of the RE-TyPE study are:

  1. To improve understanding of the early clinical course of intermediate-high risk pulmonary embolism and its association with outcome and
  2. To establish a platform for longitudinal follow-up for all pulmonary embolism at Sahlgrenska University Hospital

HYPOTHESES

  1. The dynamic pattern of change, evaluated thorough repeated measures of biomarkers, electrocardiography and echocardiography during the first 48 hours after pulmonary embolism, better predicts outcome than static measurements currently used to predict outcome
  2. Establishment of a platform for longitudinal follow-up will improve quality of care and outcome for patients with pulmonary embolism at Sahlgrenska University Hospital

연구 개요

상태

모병

정황

상세 설명

BACKGROUND

Pulmonary embolism (PE) is the third most common acute cardiovascular condition and remains associated with substantial morbidity and mortality. Although advances in therapy have reduced overall mortality, optimal treatment within the intermediate-high risk group remains uncertain. In parallel, knowledge of long-term outcomes after PE in Sweden is incomplete, largely due to the absence of a dedicated national PE registry.

Risk stratification of PE has evolved into the current four-tier European Society of Cardiology (ESC) classification, supported by clinical risk scores such as the Pulmonary Embolism Severity Index (PESI). The intermediate-high risk group is especially challenging due to marked heterogeneity in clinical course, ranging from rapid recovery to sudden deterioration. Existing risk scores were mainly developed to identify low risk patients and provide limited guidance on predicting deterioration, largely due to low positive predictive value.

Current risk stratification relies on static, single-timepoint variables, despite PE being a dynamic disease. Prospective studies evaluating the early temporal course of PE are scarce and typically focus on isolated parameters, with no studies integrating repeated clinical, imaging, and biomarker assessments.

The RE-TyPE study aims to address these gaps by characterizing the early clinical course of intermediate-high risk PE and linking this to short- and medium-term outcomes. The study will also provide a platform for long-term follow-up, evaluation of treatment strategies, and a research infrastructure dedicated to all PE at Sahlgrenska University Hospital.

AIM, OBJECTIVES AND METHODS

The overarching research aim is to characterize the early clinical course of intermediate-high risk PE to identify phenotypes associated with poor outcome (Cohort A), and to investigate intermediate- and long-term outcome and outpatient care for all PE cases at Sahlgrenska University Hospital (Cohort B).

PRIMARY OBJECTIVES

Cohort A - prospective phenotyping (admitted intermediate-high risk PE):

To collect in-dept data regarding the early clinical course of PE, including temporal changes in vital signs, ECG, echocardiography and biomarkers from baseline (day 0, PE-event) until day 2, and to analyse its association with in-hospital clinical outcome day 0-7.

Cohort B - follow-up (all PE):

To collect in-dept baseline data, including vital signs, ECG, echocardiography and biomarkers, and to analyse its association with intermediate and long-term outcome (>12 months)

SCEONDARY OBJECTIVES

Cohort A - prospective phenotyping:

  1. To collect in-dept data regarding the early clinical course of PE, including temporal changes in vital signs, ECG, echocardiography and biomarkers from baseline (day 0, time of first biomarkers associated with PE-event) until day 2, and to analyse its association with clinical outcome at day 30
  2. To examine the timing of thrombolysis and/or thrombectomy in relation to in-hospital (day 0-7), short-term (day 30) and medium-term (~90 days) outcome
  3. To investigate the value of in-hospital 1-minute sit-to-stand test in predicting clinical outcomes in-hospital (day 0-7), short-term (day 30) and medium-term (~90 days) outcome
  4. To investigate the correlation between radiological signs of right ventricular strain (increased right ventricle/left ventricle, RV/LV, -ratio and echocardiographic signs of right ventricular strain

Cohort B - registry (all PE)

B. Cohort B - follow-up (all PE)

  1. Evaluate prognostic implications of clinical phenotypes (based on clinical course for cohort A and based on baseline variables for cohort B) by assessing associations with long-term (1-year) patient-reported outcome measures (PROMs) according to the Pulmonary Embolism Quality of Life Questionnaire (PEmb-QoL), Post Vte Functional Scale (PVFS) or EuroQol 5-Dimension (EQ5D) questionnaire.
  2. Evaluate prognostic implications of clinical phenotypes (based on clinical course day 0-2 for cohort A and based on baseline variables day 0 for cohort B) by assessing associations with long-term (1-year) outcome including CTEPH as well as mortality, recurrent VTE and bleeding.
  3. To assess admission rate and outcome for low risk symtomatic and low risk incidental PE

STUDY DESIGN

The RE-TyPE study combines two observational study approaches:

A) A prospective observational cohort study of hospitalized patients with intermediate-high risk PE

and

B) A follow-up cohort including all patients followed or scheduled for follow-up for PE at the outpatient clinics of Sahlgrenska University Hospital

Prospective observational study (Cohort A)

Hospitalized patients with intermediate-high risk PE at any of the three sites of Sahlgrenska University Hospital (Sahlgrenska, Östra or Mölndal) are eligible for inclusion within 48 hours of PE-diagnosis (patients included 24-48 hours post PE will be considered late inclusions and will enter the study at day 1). This constitutes patients presenting with primary PE as well as patients who are admitted for other causes and suffer from PE while admitted. Inclusion will be performed Mondays to Fridays.

After verbal and written informed consent, the patient will be included in RE-TyPE cohort A and undergo serial repeated examinations at three time-points day 0 (0h, 6±2h and 12±4h where time of first biomarker is considered zero sample index-time), day 1 (24 ± 6h) and day 2 (48 ± 8h), including vital parameters; pharmacologic treatment including oxygen therapy, thrombolysis and thrombectomy; respiratory and circulatory support; echocardiography, ECG, laboratory blood work-up, blood samples for biobanking, complications and outcome.

The majority of examinations will be performed at the hospital ward where the patient is admitted. Full echocardiographic evaluation at baseline (day 0) will be performed at the department of Clinical Physiology whereas follow-up echocardiographic examinations day 1 and 2 will be performed bedside (Point Of Care UltraSound, POCUS) at the ward where the patient is admitted. Follow-up will be scheduled to 30 (± 48h) and approximately day 90 (routine clinical follow-up).

PE follow-up cohort (Cohort B)

Cohort B constitutes all PE patients all patients followed or scheduled for follow-up for PE at the outpatient clinics of Sahlgrenska University Hospital. Therefore, patients in Cohort A who geographically belong to Sahlgrenska University Hospital are also included in Cohort B. Patients only included in Cohort B (i.e. not existing in Cohort A) are patients with low, intermediate-low or high risk PE, or patients with intermediate-high risk PE who were not identified for inclusion (i.e. missed cases eligible for Cohort A).

PE patients discharged from the emergency department (ED) or admitted low-risk PE may be included in Cohort B after informed consent during ED visit or hospitalization (provided they geographically belong to Sahlgrenska University Hospital). However, patients in Cohort B will mainly be included at their outpatient follow-up visit. Only patients in Cohort A will be subjected to the prospective serial evaluations explained above. The PE patients outside of Cohort A will be "follow-up only" patients. For these patients, only baseline day 0, day 90 and long-term variables will be collected.

Cancer associated PE

Patients who suffer from PE during active oncologic treatment are managed by the Department of Oncology at Sahlgrenska University Hospital. Aside from the oncologic treatment, the oncology department also handles the treatment and follow-up of the PE (sometimes in collaboration with consults at the internal medicine department). To bridge this gap, we will establish a collaboration with the oncology department regarding RE-TyPE, which will involve a specific contact person at the Department of Oncology regarding this study. Patients with cancer associated PE are eligible for inclusion in Cohort A or B.

Analytical and statistical considerations

The clinical course (PE phenotype) during day 0-2 will be characterized by recovery or persistence of right ventricular dysfunction, ECG changes, and biomarker levels. Right ventricular function will be assessed by TAPSE and RV/LV ratio; ECG findings include septal T-wave inversions, S1Q3T3 pattern, and right axis deviation; biomarkers include lactate, NT-proBNP and troponin I.

Because measurements are repeated over time, mixed-effects models will be used to estimate average levels and trajectories. Linear mixed models will be applied for continuous variables and generalized mixed models for binary variables.

Associations between phenotype (early clinical course day 0-2) and subsequent outcome (day 2-7) will be analysed using joint models combining mixed-effects models with Cox regression. Multivariable models will adjust for baseline confounders including age, sex, PE risk class, cancer, thrombus burden and reperfusion therapy.

The sample size will be based on the association between clinical course and the primary clinical outcome (clinical deterioration). In Cohort A, the expected 7-day deterioration is approximately 10%. The sample size calculation is based on a binary predictor (e.g. "severe clinical phenotype" yes or no), and an expected 6% vs 14% clinical deterioration proportion in the non-severe vs severe group (corresponding to 10% total outcome). Using a two-sided α = 0.05, 80% power, and an expected hazard ratio (HR) of approximately 2.5 the required sample size would be slightly over 350 patients. Adding the possibility of 10-15% of the events occurring before day two, 400 patients would be an optimal sample size (https://riskcalc.org/samplesize/).

CENTRAL DEFINITIONS

Main definitions

  • Low risk PE: Hemodynamic stable, normal right ventricular function, cardiac biomarkers normal/low (clinical risk scores low)
  • Intermediate-low risk PE: Hemodynamic stable, either right ventricular dysfunction or positive cardiac biomarkers
  • Intermediate-high risk PE: Hemodynamic stable, right ventricular dysfunction and positive cardiac biomarkers
  • High risk PE: Hemodynamic instability, right ventricular dysfunction and positive cardiac biomarkers
  • Hemodynamic instability: Systolic BP < 90 mmHg for >15 minutes, or need for vasopressors, or Signs of shock
  • ISTH definition for major bleeding: Clinically overt bleeding that is fatal; or occurs in a critical area or organ; or is associated with a fall in haemoglobin of >20 g/L; or leading to transfusion of ≥ 2 units of blood.

PRELIMINARY RESULTS

Within in the intermediate-high risk group of PE, current ESC risk stratification method, combining right ventricular dysfunction with biomarkers suggesting myocardial injury, has insufficient positive predictive value to detect who will deteriorate or not. No markers in isolation or in combination have proven sufficient to predict which patients will deteriorate. Risk prediction tools such PESI has also displayed low positive predictive value for detecting patients who will need more advanced treatment. This further emphasizes the relevance of the RE-TyPE project.

The RE-TyPE protocol is finalized and the study has recieved ethical approval from the Swedish Ethical Review Authority (approval number 2026-00503-01).

ETHICAL CONSIDERATIONS

Patients will be included after verbal and written informed consent. The principal investigators and co-investigators (physicians as well as nurses) involved in the study may include patients. The added examinations outside of clinical routine carry no risk for serious adverse events. The study has been ethically approved and will be conducted in accordance with the declaration of Helsinki. Contact has been established with Gothia Forum regarding this specific project for quality assurance.

SCIENTIFIC IMPORTANCE

RE-TyPE is the first study to perform serial investigations using multiple modalities to phenotype PE. This approach with serial investigations of intermediate-high risk PE enables a unique possibility of linking high resolution clinical phenotyping with early, intermediate and long-term outcome. There are numerous studies on single time-point predictors. In contrast to these static measurements, RE-TyPE captures dynamic disease patterns, enabling identification of distinct clinical phenotypes defined by their trajectories rather than static measurements. Also, the follow-up part of RE-TyPE (Cohort B) provide knowledge regarding intermediate- and long-term outcome and enables evaluation of the regional outpatient clinical care of PE patients. If successful, the RE-TyPE-study could significantly improve the quality and safety of care for PE patients.

연구 유형

관찰

등록 (추정된)

400

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

  • 이름: Mazdak Tavoly, MD, PhD
  • 전화번호: +46313421000

연구 장소

    • Region Västra Götaland
      • Gothenburg, Region Västra Götaland, 스웨덴
        • 아직 모집하지 않음
        • Sahlgrenska University Hospital/Mölndal
      • Gothenburg, Region Västra Götaland, 스웨덴
        • 모병
        • Sahlgrenska University Hospital/Sahlgrenska
        • 연락하다:
      • Gothenburg, Region Västra Götaland, 스웨덴
        • 아직 모집하지 않음
        • Sahlgrenska University Hospital/Östra

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Adult patients diagnosed with pulmonary embolism during routine clinical care at Sahlgrenska University Hospital in Gothenburg. Patients are identified through hospital services responsible for the diagnosis and management of pulmonary embolism within the regional healthcare system of Region Västra Götaland (Sweden).

설명

Inclusion Criteria:

  1. Adult patients (≥ 18 years old) who is diagnosed with, or followed as out-patients for, PE at Sahlgrenska University Hospital
  2. Written informed consent

Exclusion Criteria from Cohort A:

  1. Low risk, intermediate-low risk or high risk PE*
  2. >48 hours since PE diagnosis
  3. Expected inability to comply with the protocol (e.g. dementia)

Exclusion Criterium from Cohort B:

1. Not geographically belonging to Sahlgrenska University Hospital

*If biomarkers (and/or echocardiography) are not available in hemodynamically stable patients, RV/LV-ratio >1 will be considered as preliminary intermediate-high risk. If biomarkers later fall out negative, the patient will be considered as intermediate-low risk and will be moved to Cohort B

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
Cohort A

Intermediate-high risk pulmonary embolism admitted to Sahlgrenska University Hospital - prospective phenotyping thorugh serial investigations day 0, 1, 2 30 and 90.

Cohort B

All risk classes of pulmonary embolism scheduled for follow-up at Sahlgrenska University Hospital - retrospective and prospective phenotyping at day 0, 90 (inclusion) and >12 months (Cohorts overlap since all patients in Cohort A who geographically belong to Sahlgrenska University Hosptial are also part of Cohort B)

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Clinical deterioration
기간: 7 days

The composite of: All-cause death, cardiac arrest, hemodynamic decompensation (systolic blood pressure <90 mmHg, need of vasopressor, clinical signs of hypoperfusion or fall of systolic blood pressure >40 mmHg in 15 minutes), respiratory failure (need of respiratory support such as high-flow nasal oxygen, non-invasive ventilation or intubation), escalation to rescue reperfusion therapy (thrombolysis, thrombectomy/FlowTriever, surgery), National Early Warning Score 2 (NEWS2) -score ≥7 or transfer to intensive care unit ("IVA" as defined at Sahlgrenska) due to PE. Each individual outcome will also be analysed independently.

7 days
Major bleeding
기간: 7 days

According to ISTH (International Society on Thrombosis and Haemostasis) as fatal bleeding, and/or symptomatic bleeding in a critical area or organ (such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial), or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin levels of 20 g/L or greater, or leading to a transfusion of 2 units or more of whole blood or red cells.

7 days

2차 결과 측정

결과 측정
측정값 설명
기간
Death, VTE recurrence or major bleeding
기간: 30 days

Death (all-cause), recurrent VTE or major bleeding (according to ISTH)

30 days
Death, VTE recurrence or major bleeding
기간: 90 days

Death (all-cause), recurrent VTE or major bleeding (according to ISTH)

90 days
Death, VTE recurrence or major bleeding
기간: 365 days

Death (all-cause), recurrent VTE or major bleeding (according to ISTH)

365 days
Chronic ThromboEmbolic Pulmonary Hypertension (CTEPH)
기간: 180 days

Patient medical chart CTEPH diagnosis at long-term follow up

180 days
Patient reported outcome measures (PROMs)
기간: 90 days

According to Pulmonary Embolism Quality of Life score (PEmb-QoL)

90 days
Patient reported outcome measures (PROMs)
기간: 90 days

According to Post-Venous Thromboembolism Functional Status scale (PVFS)

90 days
Patient reported outcome measures (PROMs)
기간: 90 days

EuroQol 5-Dimension (EQ5D) questionnaire

90 days
Admission rate for low risk PE
기간: 365 days

Admission rate (patients admitted/diagnosed) for low risk symtomatic or low risk incidental PE

365 days
Outcome for low risk PE
기간: 365 days

Death, recurrent VTE or major bleeding for low risk symtomatic PE or low risk incidental PE

365 days
Clinically relevant non-major bleeding (CRNMB)
기간: 365 days

Clinically relevant non-major bleeding (CRNMB, Kaatz et al 2015) defined as any overt sign of hemorrhage that does not meet the criteria for major bleeding, but requires a medical intervention, such as a face-to-face evaluation or hospitalization.

365 days

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 4월 1일

기본 완료 (추정된)

2030년 1월 1일

연구 완료 (추정된)

2032년 1월 1일

연구 등록 날짜

최초 제출

2026년 3월 11일

QC 기준을 충족하는 최초 제출

2026년 3월 19일

처음 게시됨 (실제)

2026년 3월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 7일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2026-00503-01 (registr. nr.)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .